The ability to accurately and rapidly evaluate SARS-CoV-2 half-maximal neutralizing antibody (nAb) titer (NT50) has important applications for research, including evaluation of prophylactic vaccines in immunocompromised adults, assessment of potential efficacy of protection against future SARS-CoV-2 infection in individuals receiving prophylactic monoclonal antibodies, and monitoring of COVID-19 disease severity. In this webinar, we will show you how the Bio‑Plex Pro Human SARS-CoV-2 Neutralization Antibody nAb assay could provide a rapid, high-throughput, culture-free method for NT50 determination in sera for current and future SARS-CoV-2 variants.
In this webinar you will learn how:
- Accurate and rapid evaluation of 50% neutralizing antibody titer (NT50) has important applications for COVID-19 research
- To use the Bio‑Plex Pro Human SARS-CoV-2 Neutralization Antibody Assay to determine NT50 in sera
- To validate the Bio‑Plex NT50 assay for new SARS-CoV-2 variants developed using the Bio‑Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit
Urvi M Parikh, PhD,
Associate Professor of Medicine, University of Pittsburgh School of Medicine, Division of Infectious Diseases
Urvi M Parikh, PhD, Associate Professor of Medicine at the University of Pittsburgh, is a translational virologist, whose SARS-CoV-2 work focuses evaluating serological responses to SARS-CoV-2 infection in healthy or immunocompromised individuals who have received monoclonal antibodies to prevent infection or disease progression. She has been involved in numerous large-scale COVID-19 studies conducted through the AIDS Clinical Trials Group (ACTG) and the University of Pittsburgh Medical Center. In addition, she is very active in the HIV field, studying risk of HIV drug resistance with the use of pre-exposure prophylaxis to prevent HIV infection.
Vanitha Margan,
Global Product Manager, Bio‑Plex Immunoassays
Vanitha Margan is the Global Product Manager for the Immunoassays Team at Bio‑Rad Laboratories. She graduated with a Bachelor of Applied Science from Swinburne University of Technology, Australia with a double major in Biochemistry and Chemistry. She earned her MBA from the University of Phoenix, USA. She started her career as a medical laboratory scientist in a clinical laboratory and has held field application specialist and sales roles for a clinical diagnostics and life science products distributor in Malaysia. Since joining Bio‑Rad in 2007, she has held roles in both Clinical Diagnostics and Life Science Groups spanning from technical support, sales, regional marketing, and global commercialization marketing. Her specialties include clinical chemistry, diabetes monitoring, infectious diseases, inflammation markers, and laboratory quality control.